News

New Patent for Caretaker Medical

Caretaker Medical has received issuance of a new Patent by the United States Patent and Trademark Office (USPTO) for self-calibrating systems for blood pressure wave form analysis and diagnostics, U.S. Patent No. 11,207,034, further strengthening the Company’s intellectual property position and coverage for the Company’s medical-grade continuous digital blood pressure and vital sign monitoring system.

“We are pleased to announce this new patent that is especially important for patient care as it enables ultra-fast, 30-second auto-calibration of arterial blood pressure, which is an essential measurement for cardiovascular health. This provides a big advantage over existing continuous blood pressure monitoring systems that require additional arm cuff calibration measurements, which add costly delays to set up time and patient care,” commented Jeff Pompeo, President and Chief Executive Officer of Caretaker Medical.

Caretaker Medical, a pioneer in wireless “beat-by-beat” hemodynamic monitoring technology, now has six issued patents in the U.S., Europe, and Asia, adding to the long-term value of our medical-grade VitalStream™ continuous patient monitoring system.

Learn more about Caretaker Medical here.

Recent News

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient

08/10/2026

BIO-CAT Joins the Lallemand Family

BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation

08/04/2026

Capra advances domestic manufacturing of essential medicines with continued HHS support

Capra Biosciences, Inc., a biomanufacturing company leveraging modular, continuous bioreactor technology to enable flexible, cost-competitive domestic production of pharmaceutical ingredients, today announced continued progress under its project agreement with the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS). The additional investment brings Capra’s total ASPR